Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaShannon L. Maude, Stephan A. Grupp, Theodore W. Laetsch et al.|New England Journal of Medicine|2018Cited by 5.7k
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemiaElena J. Orlando, Wendy Winckler, Xia Han et al.|Nature Medicine|2018Cited by 577
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA TrialTheodore W. Laetsch, Stephan A. Grupp, Shannon L. Maude et al.|Journal of Clinical Oncology|2022Cited by 369
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III StudyChristina Peters, Peter Bader, Jean‐Hugues Dalle et al.|Journal of Clinical Oncology|2020Cited by 333
Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromesSushree Sangita Sahoo, David R. Betts, Irith Baumann et al.|Nature Medicine|2021Cited by 170